Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3

Methodology|Interests|Funding|Corrections

Cycle record

Assessment cycle 2026 Q3 — page 15

Documents ratified in the 2026 Q3 assessment cycle, which ran from 1 July 2026 to 30 September 2026 and was ratified on 18 September 2026.

Documents ratified

564 documents · page 15 of 15

Register entry: Jacinta Ravensworth

CEI-RG-215Register entry2026-q3

Comment-period correspondent, regulatory science. Regulatory affairs, generic medicines sector

30 Jul 2026
Register entry: Dr Constança Glendinning-Uche

CEI-RG-216Register entry2026-q3

Comment-period correspondent, health-technology assessment. Health-technology assessment agency

30 Jul 2026
Register entry: Dr Evander Ashworth-Danquah

CEI-RG-217Register entry2026-q3

Comment-period correspondent, health-technology assessment. Health-technology assessment agency

30 Jul 2026
Supplier dossier: Qingdao Saber Technology Pharmaceutical

CEI-SD-19Supplier dossier2026-q3

Peptides, SARMs, injectable oils and raw materials.

29 Aug 2026

page 15 of 15

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.